Maxime Chénard-Poirier

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 8

Top Topics

Advanced Cancer

Irritable Bowel Syndrome

Tyrosine Kinase

Top Venues

Investigational new drugs

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Sarah Er Halford, Gareth J Veal, Stephen R Wedge, Geoffrey S Payne, Chris M Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M Salisbury, Maxime Chénard-Poirier, Alastair P Greystoke, Elizabeth C Howell, William A Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C Keun, Udai Banerji, Ruth Plummer
A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Sarah Er Halford, Gareth J Veal, Stephen R Wedge, Geoffrey S Payne, Chris M Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M Salisbury, Maxime Chénard-Poirier, Alastair P Greystoke, Elizabeth C Howell, William A Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C Keun, Udai Banerji, Ruth Plummer
A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Bertrand Routy, Caroline Letendre, David Enot, Maxime Chénard-Poirier, Vikram Mehraj, Noémie Charbonneau Séguin, Khaled Guenda, Kathia Gagnon, Paul-Louis Woerther, David Ghez, Silvy Lachance
The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. Oncoimmunology 6 (1) (2016)